A detailed history of D.A. Davidson & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, D.A. Davidson & Co. holds 5,475 shares of VRTX stock, worth $2.47 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,475
Previous 4,864 12.56%
Holding current value
$2.47 Million
Previous $2.28 Million 11.72%
% of portfolio
0.02%
Previous 0.02%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$460.0 - $505.78 $281,060 - $309,031
611 Added 12.56%
5,475 $2.55 Million
Q2 2024

Jul 31, 2024

SELL
$392.81 - $485.53 $8,641 - $10,681
-22 Reduced 0.45%
4,864 $2.28 Million
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $989,463 - $1.08 Million
2,427 Added 98.7%
4,886 $2.04 Million
Q4 2023

Feb 09, 2024

SELL
$343.0 - $410.68 $310,072 - $371,254
-904 Reduced 26.88%
2,459 $1 Million
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $37,199 - $39,870
110 Added 3.38%
3,363 $1.17 Million
Q2 2023

Aug 10, 2023

SELL
$314.42 - $351.91 $163,812 - $183,345
-521 Reduced 13.8%
3,253 $1.14 Million
Q1 2023

Apr 25, 2023

SELL
$283.23 - $323.1 $160,591 - $183,197
-567 Reduced 13.06%
3,774 $1.19 Million
Q4 2022

Feb 03, 2023

BUY
$285.76 - $321.48 $640,102 - $720,115
2,240 Added 106.62%
4,341 $1.25 Million
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $38,610 - $43,079
-141 Reduced 6.29%
2,101 $608,000
Q2 2022

Jul 28, 2022

BUY
$234.96 - $292.55 $14,332 - $17,845
61 Added 2.8%
2,242 $632,000
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $209,906 - $247,399
948 Added 76.89%
2,181 $569,000
Q4 2021

Jan 31, 2022

SELL
$177.01 - $223.45 $531 - $670
-3 Reduced 0.24%
1,233 $271,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $224,198 - $250,895
1,236 New
1,236 $224,000
Q2 2021

Aug 10, 2021

SELL
$187.49 - $221.1 $174,740 - $206,065
-932 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$207.02 - $241.31 $192,942 - $224,900
932 New
932 $200,000
Q4 2020

Feb 10, 2021

SELL
$207.01 - $276.09 $174,095 - $232,191
-841 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$255.65 - $303.1 $17,895 - $21,217
70 Added 9.08%
841 $229,000
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $173,845 - $228,061
771 New
771 $224,000
Q2 2019

Aug 13, 2019

SELL
$164.61 - $190.37 $3.57 Million - $4.13 Million
-21,676 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$163.73 - $194.7 $102,167 - $121,492
-624 Reduced 2.8%
21,676 $3.99 Million
Q4 2018

Jan 29, 2019

SELL
$151.91 - $192.21 $35,395 - $44,784
-233 Reduced 1.03%
22,300 $3.7 Million
Q3 2018

Nov 13, 2018

SELL
$167.73 - $192.74 $34,552 - $39,704
-206 Reduced 0.91%
22,533 $4.34 Million
Q2 2018

Aug 02, 2018

SELL
$145.72 - $169.96 $97,923 - $114,213
-672 Reduced 2.87%
22,739 $3.87 Million
Q1 2018

May 04, 2018

SELL
$151.6 - $177.13 $45,631 - $53,316
-301 Reduced 1.27%
23,411 $3.82 Million
Q4 2017

Feb 08, 2018

SELL
$137.28 - $155.55 $182,033 - $206,259
-1,326 Reduced 5.3%
23,712 $3.55 Million
Q3 2017

Nov 08, 2017

BUY
$148.13 - $162.24 $19,701 - $21,577
133 Added 0.53%
25,038 $3.81 Million
Q2 2017

Aug 11, 2017

BUY
N/A
24,905
24,905 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.